Dehydronitrosonisoldipine

Dehydronitrosonisoldipine (DNND) is a potent calcium channel blocker that is used in the treatment of hypertension and angina pectoris. It works by inhibiting the influx of calcium ions into vascular smooth muscle cells, which results in relaxation of the blood vessels and a decrease in blood pressure. This medication is administered orally, and its effects can last for up to 24 hours. Chemically, DNND is a derivative of nifedipine, which is a well-known calcium channel blocker. DNND is an organic nitrate, which means that it contains a nitro functional group (-NO2) that can be metabolized in the body to release nitric oxide. Nitric oxide is a potent vasodilator, meaning that it can relax blood vessels and increase blood flow. DNND is metabolized in the liver by the cytochrome P450 enzyme system, and its metabolites are excreted in the urine and feces. It has a half-life of approximately 2-4 hours, and its pharmacokinetics are dose-dependent. Like all medications, DNND has potential side effects, including dizziness, headache, flushing, and hypotension. It should not be used in patients with a history of hypersensitivity to nifedipine or other calcium channel blockers, or in patients with severe liver or kidney disease. Additionally, DNND should not be used in pregnant or breastfeeding women, as its effects on fetal development and milk production are not known.